NCT07080268Withdrawn
Validation of a Questionnaire for Quality of Life Assessment in Patients With Transthyretin Amyloidosis.
Validation of a Questionnaire for Quality of Life Assessment in Patients With Transthyretin Amyloidosis in Argentina.
Source: ClinicalTrials.gov · Last updated 17 Sept 2026
Brief summary (registry, in English)
Prospective study of development and validation of a questionnaire on quality of life in patients with Hereditary Amyloidosis The questionnaire development process will include 4 medical specialists experts in Transthyretin Amyloidosis (2 neurologists, 1 cardiologist, 1 physician clinical/hepathologist), 1 psychologist; 1 social worker; and 3 patients (with confirmed Hereditary amyloidosis) members of ALAPA. (Local PAG) Population and sample:
- Status (registry)
- Withdrawn
- Study type
- Observational
- Enrollment
- 0 (actual)
- First submitted
- 15 Jul 2025
- Start date
- 20 Jun 2025
- Primary completion date
- 1 Sept 2025
- Lead sponsor
- Hospital General de Niños Pedro de Elizalde
- Diseases
- Amyloidosis
- NCT number
- NCT07080268
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- patients who participated in the validation process of the questionnaire: patients who participated in the questionnaire construction process or adjustments to the questionnaire.
Who the study is looking for
- patients with confirmed ATTR (genetic test), older than 18 years old in stage I, II and III of the PND scale (polyneuropathy disability: I Sensory neuropathy ; II Motor symptoms, but with preserved ambulation; IIIa Requires 1 cane to ambulate; IIIb requires two canes/walker).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| HGNPE Coordinator of this site? Confirm its status | Buenos Aires | Argentina | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.